Skip to main content

Adhesion

0
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Baxter
BaxterCosta Rica - Cartago
2 programs
ADEPTN/A
COSEALN/A
Baxter International
2 programs
ADEPTN/A1 trial
CosealN/A1 trial
Active Trials
NCT05811585Completed153Est. May 2024
NCT05996809Completed200Est. May 2025
Pharmasyntez
PharmasyntezRussia - Irkutsk
2 programs
SeroguardPHASE_11 trial
SeroguardPHASE_21 trial
Active Trials
NCT03640559Completed50Est. Oct 2015
NCT03660787Completed114Est. Jan 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PharmasyntezSeroguard
PharmasyntezSeroguard
Baxter InternationalCoseal
Baxter InternationalADEPT

Clinical Trials (4)

Total enrollment: 517 patients across 4 trials

Efficacy and Dose Ranging Study of Seroguard

Start: May 2017Est. completion: Jan 2018114 patients
Phase 2Completed

Safety and Tolerability of Seroguard Use

Start: May 2015Est. completion: Oct 201550 patients
Phase 1Completed

PMCF Study for COSEAL® in Gynecologic Surgery

Start: Jun 2024Est. completion: May 2025200 patients
N/ACompleted

PMCF Study for ADEPT® in LaparoscopicGynecologic Surgery

Start: Jun 2023Est. completion: May 2024153 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.